renal cell carcinoma Archives -

Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar’s bempegaldesleukin a companion drug to its

End of the line for BMS, Nektar’s bempegaldesleukin/Opdivo alliance

https://pharmaphorum.com/news/end-of-the-line-for-bms-nektars-bempegaldesleukin-alliance/

News/ News/ Oncology

Merck gets EU nod for Keytruda in adjuvant kidney cancer

Phil Taylor adjuvant, EU, immuno-oncology, Keytruda, Merck & Co, Oncology, regulatory approval, renal cell carcinoma 0 Comment

Merck & Co has passed another milestone in its drive to move PD-1 inhibitor Keytruda earlier in the

Merck gets EU nod for Keytruda in adjuvant kidney cancer

https://pharmaphorum.com/news/merck-gets-eu-nod-for-keytruda-in-adjuvant-kidney-cancer/

Oncology/ Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

Putting patient perspectives at the heart of kidney cancer research

mike.hammerton@pharmaphorum.com cancer, Ipsen, kidney cancer, patients, R&D, renal cell carcinoma, RWE 0 Comment

Commissioned by Ipsen. Ipsen’s Steven Hildemann looks at how we can harness the power of patient perspectives in

Putting patient perspectives at the heart of kidney cancer research

https://pharmaphorum.com/patients/patient-perspectives-kidney-cancer-research/

News/ News/ Oncology

Merck wins FDA nod for Keytruda as adjuvant kidney cancer treatment

Phil Taylor adjuvant, fda, immuno-oncology, Keytruda, Merck & Co, Oncology, regulatory approval, renal cell carcinoma 0 Comment

Merck & Co has chalked up another win in drive to move PD-1 inhibitor Keytruda earlier in the

Merck wins FDA nod for Keytruda as adjuvant kidney cancer treatment

https://pharmaphorum.com/news/merck-wins-fda-nod-for-keytruda-as-adjuvant-kidney-cancer-treatment/

News/ News/ Oncology

FDA starts speedy review of Keytruda for adjuvant kidney cancer

Phil Taylor adjuvant, immuno-oncology, Keytruda, Merck & Co, Oncology, renal cell carcinoma 0 Comment

Merck & Co is looking at a decision from the FDA in December on its application to market

FDA starts speedy review of Keytruda for adjuvant kidney cancer

https://pharmaphorum.com/news/fda-starts-speedy-review-of-keytruda-for-adjuvant-kidney-cancer/

News/ News/ Oncology

Merck gets a leg-up for Keytruda in first-line kidney cancer

Phil Taylor Bristol-Myers Squibb, Cabometyx, Eisai, Exelixis, immuno-oncology, Inlyta, Keytruda, Lenvima, Merck & Co, Oncology, Opdivo, Pfizer, renal cell carcinoma, Sutent, Yervoy 0 Comment

New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the

Merck gets a leg-up for Keytruda in first-line kidney cancer

https://pharmaphorum.com/news/merck-gets-a-leg-up-for-keytruda-in-first-line-kidney-cancer/

News/ News/ Oncology

FDA kicks off review of second kidney cancer combo based on BMS’ Opdivo

Phil Taylor Bristol-Myers Squibb, Cabometyx, Exelixis, immuno-oncology, Oncology, Opdivo, renal cell carcinoma 0 Comment

Bristol-Myers Squibb could be mere months away from claiming a second US approval for an Opdivo-based combination immunotherapy

FDA kicks off review of second kidney cancer combo based on BMS’ Opdivo

https://pharmaphorum.com/news/fda-starts-review-of-second-kidney-cancer-use-for-bms-opdivo/

Keeping up the PACE at the Scottish Medicines Consortium

Market Access/ News/ News

Scotland backs Merck/Pfizer’s Bavencio combo for kidney cancer

Phil Taylor Bavencio, immuno-oncology, Inlyta, Merck KGaA, Oncology, Pfizer, renal cell carcinoma, Scottish Medicines Consortium 0 Comment

The Scottish Medicines Consortium (SMC) backed NHS use of nine new medicines at its meeting this week, including

Scotland backs Merck/Pfizer’s Bavencio combo for kidney cancer

https://pharmaphorum.com/news/scotland-backs-merck-pfizers-bavencio-combo-for-kidney-cancer/

News/ News/ Oncology

BMS gets an important win for Opdivo combination in kidney cancer

Phil Taylor Bristol-Myers Squibb, Exelixis, immuno-oncology, kidney cancer, Merck & Co, Oncology, Opdivo, Pfizer, renal cell carcinoma 0 Comment

Bristol-Myers Squibb has staked another claim to the first-line kidney cancer market, with impressive new data for the

BMS gets an important win for Opdivo combination in kidney cancer

https://pharmaphorum.com/news/bms-gets-an-important-win-for-opdivo-combination-in-kidney-cancer/

Trending

renal cell carcinoma

Login